Janw Eriksson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The "twincretin" tirzepatide scored another pivotal-trial win in published results from the SURPASS-4 trial, which compared the investigational agent to insulin glargine for treatment of type 2 diabetes.

Merck sharpeJanw erikssonMelaniej daviesIlya pharmaUniversity of pisaEuropean association for the study of diabetesUniversity of leicesterGilead sciencesUppsala sweden universityDrug administrationBoehringer ingelheimNapp pharmaceuticalsNovo nordiskStefano del pratoDel pratoAppears similar